Loading
Life sciences · Journal article
Small · October 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Engineered bacteria offer promising opportunities for cancer immunotherapy, yet precise in vivo activation and real‐time tracking of immune responses remain formidable challenges. Here, we present an x‐ray‐sensitive engineered bacterium, composed of Escherichia coli ( E. coli ) and gold‐silver nanorods (Ec‐GS NRs), for synergistic radioimmunotherapy and photoacoustic (PA) immunomonitoring of triple‐negative breast cancer (TNBC). Upon x‐ray irradiation, Ag + release induces bacterial damage, stimulating the host immune system and triggering immunogenic tumor cell death. Moreover, radiation‐induced etching alters nanorod optoacoustic properties, enabling noninvasive PA monitoring of immunotherapy initiation. In TNBC models, Ec‐GS NRs combined with x‐ray irradiation achieved near‐complete tumor regression through enhanced radioimmunotherapy. Concurrently, PA signal ratio (PA 808 /PA 1064 ) increased 127‐fold, allowing in situ monitoring of immune activation. Notably, Ec‐GS NRs elicited a strong abscopal effect, suppressing distant metastases and extending overall survival. This study thus establishes a bacteria‐enabled radioimmunotheranostic strategy integrating x‐ray‐controllable immune activation, radiosensitization, and PA‐immunomonitoring to address limitations in precision cancer therapy.